Aimmune Therapeutics (AIMT) Misses Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Join SI Premium – FREE
Aimmune Therapeutics (NASDAQ: AIMT) reported Q4 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35).
For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
